Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149549 · ClinicalTrials.gov registry record · Phase 1
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
A Phase 1 study, sponsored by CytomX Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT03149549 is a Phase 1 study that was terminated before completion, run by CytomX Therapeutics. The registered enrollment target is 99 participants.
The verdict
NCT03149549, a Phase 1 study, was terminated before completion, sponsored by CytomX Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
Interventions
- DRUG CX-2009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149549
The ClinicalTrials.gov registry entry for NCT03149549 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CX-2009 is the first listed.
NCT03149549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149549 about?
NCT03149549 is a clinical study titled "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors". The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Ma...
What is the current status of trial NCT03149549?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2017-06-01. Estimated completion is 2020-09-10.
What interventions are being tested in trial NCT03149549?
The interventions under investigation include: CX-2009 (DRUG).
Who is sponsoring clinical trial NCT03149549?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.